Alps Advisors Inc Zynerba Pharmaceuticals, Inc. Transaction History

Alps Advisors Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Jul 31, 2018	SELL	$7.98 - $12.39 $290,120 - $450,450	-36,356 Reduced 70.77%	15,019 $188,000
Q2 2018 Jul 25, 2018	BUY	$7.98 - $12.39 $119,851 - $186,085	15,019 Added 41.31%	51,375 $504,000
Q1 2018 May 01, 2018	BUY	$8.49 - $13.46 $181,151 - $287,196	21,337 Added 142.07%	36,356 $316,000
Q4 2017 Feb 05, 2018	BUY	$8.69 - $14.59 $17,110 - $28,727	1,969 Added 15.09%	15,019 $188,000
Q3 2017 Nov 03, 2017	BUY	$5.73 - $9.44 $74,776 - $123,192	13,050	13,050 $109,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.